Skip to content

A Study of Wrist Worn Accelerometers in End-Stage Renal Disease

A Feasibility Study of a Wrist Worn Accelerometer to Characterise the Physical Activity of Patients With End-stage Renal Disease (W-WARD Study).

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04860440
Acronym
W-WARD
Enrollment
40
Registered
2021-04-27
Start date
2021-07-31
Completion date
2022-03-31
Last updated
2021-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Diseases, End Stage Renal Disease on Dialysis, Frailty

Brief summary

The kidneys are important at getting rid of toxins and excess water from the body. If they fail, then toxins and excess water builds up within the body. Kidney failure is treated by either giving patients a new kidney (a transplant) or by removing the toxins and fluid from the body by the process of dialysis. The investigators' aim is to personalise the care given to patients with kidney failure, and as such, they have started measuring the fitness of patients with kidney failure, who either already require dialysis or may need dialysis in the near future. This is currently done in a number of ways including measuring how strong their grip is, assessing their walking speed and asking questions about how difficult they find certain activities. In the future, the investigators think that this will allow targeted treatments to help improve their fitness and potentially identify any problems earlier. Current approaches to measuring activity and fitness have limitations and in particular may over- or underestimate the level of the physical activity. To over come these limitations, participants will be asked to wear an activity tracker (called an accelerometer) on for a week. Readings from the accelerometer will be compared against the other markers of fitness and activity to see if they are comparable. It will also be noted whether patients are prepared to wear the device for 7 days (compliance).

Interventions

DEVICEGeneActiv wrist worn accelerometer

Wrist worn device worn for 7 days

Sponsors

University of Cambridge
CollaboratorOTHER
Cambridge University Hospitals NHS Foundation Trust
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Aged over 18 years with low clearance pre-dialysis and referred to the Low Clearance Clinic with estimated Glomerular Filtration Rate (eGFR) less than 20 ml/min/1.73m and / or commenced on haemodialysis 2. Able to give informed consent

Exclusion criteria

1. Significant resting tremor of any aetiology or severe Parkinson's Disease 2. Immobile 3. Arteriovenous fistulas in both arms 4. Any scheduled inpatient treatment or day case treatment in next 7 days.

Design outcomes

Primary

MeasureTime frameDescription
Acceptability7 daysThe acceptability of physical activity measures in frailty assessment in patients from the low clearance and dialysis clinic as determined by the percentage of time, device worn during the 7-day period.

Secondary

MeasureTime frameDescription
Fried Frailty Phenotype (no units)1 dayFried Frailty Phenotype (no units)
Grip strength (in kilograms)1 dayGrip strength (in kilograms)
Walking speed (in seconds measured over 15 feet)1 dayWalking speed (in seconds measured over 15 feet)
Measurement of physical activity by the accelerometer7 daysMeasurement of physical activity by the accelerometer (no units)
10 Point Cognitive Screener (no units)1 day10 Point Cognitive Screener (no units)
4AT Assessment Tool of Cognitive Impairment (no units)1 day4AT Assessment Tool of Cognitive Impairment (no units)
Clinical Frailty Scale (no units)1 dayClinical Frailty Scale (no units)

Countries

United Kingdom

Contacts

Primary ContactJames A Richards
James.richards@addenbrookes.nhs.uk01223 245 151

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026